HR-17020

The main objectives are: 1) To compare the differences in the pharmacokinetic characteristics of single and multiple subcutaneous injections of HR17020 2.5 mg and 3.75 mg for injection after reaching steady state in healthy subjects, and to evaluate the magnitude of the in vivo accumulation effect of apixaban; the secondary objectives are: 2) To evaluate the safety and tolerability of multiple consecutive administrations of HR17020 2.5 mg and 3.75 mg for injection in healthy subjects.